[1]
Park MS, Yang YM, Kim JS, Choi EJ. Comparative study of antiretroviral drug regimens and drug-drug interactions between younger and older HIV-infected patients at a tertiary care teaching hospital in South Korea. Therapeutics and clinical risk management. 2018:14():2229-2241. doi: 10.2147/TCRM.S175704. Epub 2018 Nov 12
[PubMed PMID: 30519031]
Level 2 (mid-level) evidence
[2]
Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA. 1996 Jul 10:276(2):118-25
[PubMed PMID: 8656503]
Level 1 (high-level) evidence
[3]
Greig SL, Deeks ED. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection. Drugs. 2015 Apr:75(5):503-14. doi: 10.1007/s40265-015-0361-6. Epub
[PubMed PMID: 25698454]
[4]
Anderson PL, Kakuda TN, Kawle S, Fletcher CV. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS (London, England). 2003 Oct 17:17(15):2159-68
[PubMed PMID: 14523272]
[5]
Yuen GJ, Weller S, Pakes GE. A review of the pharmacokinetics of abacavir. Clinical pharmacokinetics. 2008:47(6):351-71
[PubMed PMID: 18479171]
[6]
Singh RP, Adkison K, Wolstenholme A, Hopking J, Wynne B. Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. Clinical pharmacology in drug development. 2021 Sep:10(9):985-993. doi: 10.1002/cpdd.996. Epub 2021 Jul 15
[PubMed PMID: 34265164]
[7]
Archary M, Mcllleron H, Bobat R, LaRussa P, Sibaya T, Wiesner L, Hennig S. Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomes. British journal of clinical pharmacology. 2019 Sep:85(9):2066-2075. doi: 10.1111/bcp.13998. Epub 2019 Jul 7
[PubMed PMID: 31141195]
[8]
Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, Sax PE, Smith DM, Thompson MA, Buchbinder SP, Del Rio C, Eron JJ Jr, Fätkenheuer G, Günthard HF, Molina JM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2018 Jul 24:320(4):379-396. doi: 10.1001/jama.2018.8431. Epub
[PubMed PMID: 30043070]
[9]
Postorino MC, Quiros-Roldan E, Maggiolo F, Di Giambenedetto S, Ladisa N, Lapadula G, Lorenzotti S, Sighinolfi L, Castelnuovo F, Di Pietro M, Gotti D, Mazzini N, Torti C, MASTER Study Group. Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function. The open AIDS journal. 2016:10():136-43. doi: 10.2174/1874613601610010136. Epub 2016 Jul 15
[PubMed PMID: 27563366]
[10]
Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, Boggian K, Chave JP, Bernasconi E, Egger M, Opravil M, Rickenbach M, Francioli P, Telenti A. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2001 Dec 1:33(11):1931-7
[PubMed PMID: 11692306]
[11]
Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2001 Dec 1:33(11):1914-21
[PubMed PMID: 11692304]
Level 3 (low-level) evidence
[12]
Carr A. HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS (London, England). 2003 Apr:17 Suppl 1():S141-8
[PubMed PMID: 12870540]
[13]
Strategies for Management of Anti-Retroviral Therapy/INSIGHT, DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS (London, England). 2008 Sep 12:22(14):F17-24. doi: 10.1097/QAD.0b013e32830fe35e. Epub
[PubMed PMID: 18753925]
[14]
D:A:D Study Group, Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, Friis-Møller N, Kirk O, Pradier C, Weller I, Phillips AN, Lundgren JD. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet (London, England). 2008 Apr 26:371(9622):1417-26. doi: 10.1016/S0140-6736(08)60423-7. Epub 2008 Apr 2
[PubMed PMID: 18387667]
[15]
Marcus JL, Neugebauer RS, Leyden WA, Chao CR, Xu L, Quesenberry CP Jr, Klein DB, Towner WJ, Horberg MA, Silverberg MJ. Use of Abacavir and Risk of Cardiovascular Disease Among HIV-Infected Individuals. Journal of acquired immune deficiency syndromes (1999). 2016 Apr 1:71(4):413-9. doi: 10.1097/QAI.0000000000000881. Epub
[PubMed PMID: 26536316]
[16]
Di L, Balesano A, Jordan S, Shi SM. The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation. The AAPS journal. 2021 Jan 7:23(1):20. doi: 10.1208/s12248-020-00536-y. Epub 2021 Jan 7
[PubMed PMID: 33415501]
[17]
Lucas A, Nolan D, Mallal S. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. The Journal of antimicrobial chemotherapy. 2007 Apr:59(4):591-3
[PubMed PMID: 17317695]
[18]
Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, Christiansen FT. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet (London, England). 2002 Mar 2:359(9308):727-32
[PubMed PMID: 11888582]
[19]
Christensen ES, Jain R, Roxby AC. Abacavir/Dolutegravir/Lamivudine (Triumeq)-Induced Liver Toxicity in a Human Immunodeficiency Virus-Infected Patient. Open forum infectious diseases. 2017 Summer:4(3):ofx122. doi: 10.1093/ofid/ofx122. Epub 2017 Jun 12
[PubMed PMID: 28748198]
[20]
de Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PloS one. 2013:8(5):e63623. doi: 10.1371/journal.pone.0063623. Epub 2013 May 28
[PubMed PMID: 23723990]
Level 1 (high-level) evidence
[21]
Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, Brumme CJ, Brumme ZL, Mo T, Alexander CS, Montaner JS. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. The Journal of infectious diseases. 2005 Feb 1:191(3):339-47
[PubMed PMID: 15633092]
[22]
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Mehendale S, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Wang L, Makhema J, Mills LA, de Bruyn G, Sanne I, Eron J, Gallant J, Havlir D, Swindells S, Ribaudo H, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano D, Essex M, Fleming TR, HPTN 052 Study Team. Prevention of HIV-1 infection with early antiretroviral therapy. The New England journal of medicine. 2011 Aug 11:365(6):493-505. doi: 10.1056/NEJMoa1105243. Epub 2011 Jul 18
[PubMed PMID: 21767103]
Level 3 (low-level) evidence
[23]
Metsch LR, Pereyra M, Messinger S, Del Rio C, Strathdee SA, Anderson-Mahoney P, Rudy E, Marks G, Gardner L, Antiretroviral Treatment and Access Study (ARTAS) Study Group. HIV transmission risk behaviors among HIV-infected persons who are successfully linked to care. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008 Aug 15:47(4):577-84. doi: 10.1086/590153. Epub
[PubMed PMID: 18624629]
[24]
Tripathi A, Youmans E, Gibson JJ, Duffus WA. The impact of retention in early HIV medical care on viro-immunological parameters and survival: a statewide study. AIDS research and human retroviruses. 2011 Jul:27(7):751-8. doi: 10.1089/AID.2010.0268. Epub 2011 Jan 15
[PubMed PMID: 21142607]
[25]
Gardner LI, Metsch LR, Anderson-Mahoney P, Loughlin AM, del Rio C, Strathdee S, Sansom SL, Siegal HA, Greenberg AE, Holmberg SD, Antiretroviral Treatment and Access Study Study Group. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS (London, England). 2005 Mar 4:19(4):423-31
[PubMed PMID: 15750396]
Level 3 (low-level) evidence
[26]
Deschamps AE, De Geest S, Vandamme AM, Bobbaers H, Peetermans WE, Van Wijngaerden E. Diagnostic value of different adherence measures using electronic monitoring and virologic failure as reference standards. AIDS patient care and STDs. 2008 Sep:22(9):735-43. doi: 10.1089/apc.2007.0229. Epub
[PubMed PMID: 18754705]
[27]
Molina JM, Podsadecki TJ, Johnson MA, Wilkin A, Domingo P, Myers R, Hairrell JM, Rode RA, King MS, Hanna GJ. A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks. AIDS research and human retroviruses. 2007 Dec:23(12):1505-14
[PubMed PMID: 18160008]
[28]
Boyle BA, Jayaweera D, Witt MD, Grimm K, Maa JF, Seekins DW. Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression. HIV clinical trials. 2008 May-Jun:9(3):164-76. doi: 10.1310/hct0903-164. Epub
[PubMed PMID: 18547903]
[29]
Dejesus E, Young B, Morales-Ramirez JO, Sloan L, Ward DJ, Flaherty JF, Ebrahimi R, Maa JF, Reilly K, Ecker J, McColl D, Seekins D, Farajallah A, AI266073 Study Group. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. Journal of acquired immune deficiency syndromes (1999). 2009 Jun 1:51(2):163-74. doi: 10.1097/QAI.0b013e3181a572cf. Epub
[PubMed PMID: 19357529]
[30]
Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, Jack W, Habyarimana J, Sadatsafavi M, Najafzadeh M, Marra CA, Estambale B, Ngugi E, Ball TB, Thabane L, Gelmon LJ, Kimani J, Ackers M, Plummer FA. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet (London, England). 2010 Nov 27:376(9755):1838-45. doi: 10.1016/S0140-6736(10)61997-6. Epub 2010 Nov 9
[PubMed PMID: 21071074]
Level 1 (high-level) evidence
[31]
Mannheimer SB, Morse E, Matts JP, Andrews L, Child C, Schmetter B, Friedland GH, Terry Beirn Community Programs for Clinical Research on AIDS. Sustained benefit from a long-term antiretroviral adherence intervention. Results of a large randomized clinical trial. Journal of acquired immune deficiency syndromes (1999). 2006 Dec 1:43 Suppl 1():S41-7
[PubMed PMID: 17091022]
Level 1 (high-level) evidence
[32]
de Bruin M, Hospers HJ, van Breukelen GJ, Kok G, Koevoets WM, Prins JM. Electronic monitoring-based counseling to enhance adherence among HIV-infected patients: a randomized controlled trial. Health psychology : official journal of the Division of Health Psychology, American Psychological Association. 2010 Jul:29(4):421-8. doi: 10.1037/a0020335. Epub
[PubMed PMID: 20658830]
Level 1 (high-level) evidence
[33]
Sabin LL, DeSilva MB, Hamer DH, Xu K, Zhang J, Li T, Wilson IB, Gill CJ. Using electronic drug monitor feedback to improve adherence to antiretroviral therapy among HIV-positive patients in China. AIDS and behavior. 2010 Jun:14(3):580-9. doi: 10.1007/s10461-009-9615-1. Epub
[PubMed PMID: 19771504]
[34]
Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2007 Sep 15:45(6):770-8
[PubMed PMID: 17712763]
Level 1 (high-level) evidence
[35]
Macalino GE, Hogan JW, Mitty JA, Bazerman LB, Delong AK, Loewenthal H, Caliendo AM, Flanigan TP. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS (London, England). 2007 Jul 11:21(11):1473-7
[PubMed PMID: 17589194]
Level 1 (high-level) evidence
[36]
Maru DS, Bruce RD, Walton M, Springer SA, Altice FL. Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trial. Journal of acquired immune deficiency syndromes (1999). 2009 Feb 1:50(2):176-81. doi: 10.1097/QAI.0b013e3181938e7e. Epub
[PubMed PMID: 19131891]
Level 1 (high-level) evidence
[37]
Safren SA, O'Cleirigh C, Tan JY, Raminani SR, Reilly LC, Otto MW, Mayer KH. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health psychology : official journal of the Division of Health Psychology, American Psychological Association. 2009 Jan:28(1):1-10. doi: 10.1037/a0012715. Epub
[PubMed PMID: 19210012]
Level 1 (high-level) evidence